Vivesto — Board/Management Information 2013

Feb 11, 2013

PRESS RELEASE

OasmiaPharmaceutical strengthens its management team

Oasmia is in an exciting phase with product candidates in late stage development and with applications made for market approval. With the intention to make management more effective, fourmore personsare added to themanagementteam.

Margareta Eriksson(born 1952) has been with Oasmia since 2008 , first as clinical research manager and wasin 2010 appointed toVice PresidentClinical Development.She hasa BSc Chemistry and Biology, PhD Zoology and has furthe r academic education in Pharmacology, Statistics, Computer science and English. Margareta has 30 yearsof experience within international pharmaceutical industry as manager and project leader in clinical research.

Ingela H€gglund(born 1964) joined Oasmiain 2013 as VicePresidentOperations. Ingela has a PhD in Analytical Chemistry and has 18 years of experience within international pharmaceutical industry as manager and project leader in research and development of pharmaceutical products. In her area ofresponsibility, Operations, works 30 employees out of the close to 80 employees that Oasmia has.

Mikael Asp(born1962) joined Oasmia in2013 as Head of Quality Assurance. Mikael has a Master of Science in Chemical Engineering and has 25 years of experience from several companies within international pharmaceutical industry in research and development, production, quali ty assurance andasQualified Person (QP).

John Cosby(born1962) has been with Oasmia since 2006 and is Head of Regulatory Affairs.John has aBSc, Chemistry at theUniversity of Maryland, USA. He has 30 years€experience from several companies within international life science, with responsibility for regulatory affairs and product development.

About Oasmia Pharmaceutical AB

(NASDAQ OMX: OASM) (General Standard of Frankfurt Stock Exchange: OMAX, ISIN SE0000722365) Oasmia Pharmaceutical AB develops new generations of drugs within human and veterinary oncology. The Company€s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well -established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The Company€s product development is based on its proprietary in -house research and company patents. The Company€s common stock is listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange.

€Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submittedfor publication at09.00a.m. CET onFebruary 11.•

2013-02-11

For more information, please contact: Johan Edin, acting Head of Public Relations, Oasmia Pharmaceutical AB. E -mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. German contact: D r. S•nke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt E -Mail: oasmia@edicto.de Phone: +49 (0) 69 90 55 05 51. Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse -frankfurt.de twitter.com/oasmia